Compare CRDL & ERH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRDL | ERH |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 103.7M |
| IPO Year | N/A | N/A |
| Metric | CRDL | ERH |
|---|---|---|
| Price | $1.05 | $11.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 328.2K | 23.2K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.85% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $7.97 |
| 52 Week High | $1.59 | $10.91 |
| Indicator | CRDL | ERH |
|---|---|---|
| Relative Strength Index (RSI) | 59.15 | 45.04 |
| Support Level | $0.94 | $11.70 |
| Resistance Level | $1.03 | $11.96 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 85.71 | 55.56 |
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company allocates a majority of its total assets to a sleeve that places a focus on common, preferred, and convertible preferred stocks of utility companies and the rest of its total assets to a sleeve of U.S. dollar denominated below investment grade (high yield) debt.